Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619902 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
A Phase 2 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03619902 is a Phase 2 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT03619902, a Phase 2 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
Interventions
- BIOLOGICAL Imsidolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03619902
The ClinicalTrials.gov registry entry for NCT03619902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imsidolimab is the first listed.
NCT03619902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03619902 about?
NCT03619902 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis". The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
What is the current status of trial NCT03619902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2019-01-30. Estimated completion is 2021-01-20.
What interventions are being tested in trial NCT03619902?
The interventions under investigation include: Imsidolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03619902?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.